Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13–25

Article  CAS  PubMed  Google Scholar 

Collaborators GBDMD (2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9:137–150

Article  Google Scholar 

Castren E (2013) Neuronal network plasticity and recovery from depression. JAMA Psychiat 70:983–989

Article  Google Scholar 

Cramer SC, Sur M, Dobkin BH, O’Brien C, Sanger TD, Trojanowski JQ, Rumsey JM, Hicks R, Cameron J, Chen D et al (2011) Harnessing neuroplasticity for clinical applications. Brain 134:1591–1609

Article  PubMed  PubMed Central  Google Scholar 

Castren E (2005) Is mood chemistry? Nat Rev Neurosci 6:241–246

Article  CAS  PubMed  Google Scholar 

Frost DO, Tamminga CA, Medoff DR, Caviness V, Innocenti G, Carpenter WT (2004) Neuroplasticity and schizophrenia. Biol Psychiatry 56:540–543

Article  PubMed  Google Scholar 

Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, Jurjus GJ, Dieter L, Duman RS (2013) Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol 16:69–82

Article  CAS  PubMed  Google Scholar 

Beneyto M, Meador-Woodruff JH (2008) Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33:2175–2186

Article  CAS  PubMed  Google Scholar 

Eisch AJ, Petrik D (2012) Depression and hippocampal neurogenesis: a road to remission? Science 338:72–75

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vyas A, Mitra R, Shankaranarayana Rao BS, Chattarji S (2002) Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J Neurosci 22:6810–6818

Article  CAS  PubMed  PubMed Central  Google Scholar 

MacQueen G, Frodl T (2011) The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry 16:252–264

Article  CAS  PubMed  Google Scholar 

Jaworska N, Yang XR, Knott V, MacQueen G (2015) A review of fMRI studies during visual emotive processing in major depressive disorder. World J Biol Psychiatry 16:448–471

Article  PubMed  Google Scholar 

Nissen C, Holz J, Blechert J, Feige B, Riemann D, Voderholzer U, Normann C (2010) Learning as a model for neural plasticity in major depression. Biol Psychiatry 68:544–552

Article  PubMed  Google Scholar 

Mago R, Mahajan R, Thase ME (2014) Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Rev Clin Pharmacol 7:137–145

Article  CAS  PubMed  Google Scholar 

Thase ME, Gommoll C, Chen C, Kramer K, Sambunaris A (2016) Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder. Int Clin Psychopharmacol 31:332–340

Article  PubMed  PubMed Central  Google Scholar 

Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G (2018) Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis. J Affect Disord 228:1–12

Article  CAS  PubMed  Google Scholar 

Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D (2013) Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 74:363–369

Article  CAS  PubMed  Google Scholar 

Krause-Sorio B, Kilpatrick L, Siddarth P, Ercoli L, Laird KT, Aguilar-Faustino Y, Milillo MM, Narr KL, Lavretsky H (2020) Cortical thickness increases with levomilnacipran treatment in a pilot randomised double-blind placebo-controlled trial in late-life depression. Psychogeriatrics 20:140–148

Article  PubMed  Google Scholar 

Bian H, Wang G, Huang J, Liang L, Zheng Y, Wei Y, Wang H, Xiao L, Wang H (2020) Dihydrolipoic acid protects against lipopolysaccharide-induced behavioral deficits and neuroinflammation via regulation of Nrf2/HO-1/NLRP3 signaling in rat. J Neuroinflammation 17:166

Article  CAS  PubMed  PubMed Central  Google Scholar 

Auclair AL, Martel JC, Assie MB, Bardin L, Heusler P, Cussac D, Marien M, Newman-Tancredi A, O’Connor JA, Depoortere R (2013) Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 70:338–347

Article  CAS  PubMed  Google Scholar 

Naegeli KJ, O’Connor JA, Banerjee P, Morilak DA (2013) Effects of milnacipran on cognitive flexibility following chronic stress in rats. Eur J Pharmacol 703:62–66

Article  CAS  PubMed  Google Scholar 

Matsumoto M, Tachibana K, Togashi H, Tahara K, Kojima T, Yamaguchi T, Yoshioka M (2005) Chronic treatment with milnacipran reverses the impairment of synaptic plasticity induced by conditioned fear stress. Psychopharmacology 179:606–612

Article  CAS  PubMed  Google Scholar 

Lan T, Wu Y, Zhang Y, Li S, Zhu Z, Wang L, Mao X, Li Y, Fan C, Wang W, Yu SY (2022) Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Galphai-2-PKA-ASK1 signaling pathway. J Neuroinflammation 19:117

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS (2007) A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 61:661–670

Article  CAS  PubMed  Google Scholar 

Walsh RN, Cummins RA (1976) The open-field test: a critical review. Psychol Bull 83:482–504

Article  CAS  PubMed  Google Scholar 

Keers R, Uher R (2012) Gene-environment interaction in major depression and antidepressant treatment response. Curr Psychiatry Rep 14:129–137

Article  PubMed  Google Scholar 

Bruno A, Morabito P, Spina E, Muscatello MR (2016) The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol 14:191–199

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SM, Dong TS, Krause-Sorio B, Siddarth P, Milillo MM, Lagishetty V, Datta T, Aguilar-Faustino Y, Jacobs JP, Lavretsky H (2022) The intestinal microbiota as a predictor for antidepressant treatment outcome in geriatric depression: a prospective pilot study. Int Psychogeriatr 34:33–45

Article  PubMed  Google Scholar 

Naguy A (2021) Levomilnacipran for negative symptom domain schizophrenia. Prim Care Companion CNS Disord 23

Rizvi SM, Shaikh S, Khan M, Biswas D, Hameed N, Shakil S (2014) Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1. CNS Neurol Disord Drug Targets 13:1427–1431

Article  PubMed  Google Scholar 

Masi G, Brovedani P (2011) The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs 25:913–931

Article  CAS  PubMed  Google Scholar 

MacQueen GM, Yucel K, Taylor VH, Macdonald K, Joffe R (2008) Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol Psychiatry 64:880–883

Article  PubMed  Google Scholar 

Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HB, Friedman L, Rajkowska G (2004) Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 56:640–650

Article  PubMed  PubMed Central  Google Scholar 

Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J, Burton LE, Stanton BR, Kaplan DR, Hunter T et al (1991) The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 65:895–903

Article  CAS  PubMed  Google Scholar 

Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15:1768–1777

Article  CAS  PubMed  PubMed Central  Google Scholar 

Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, Voshaar RC, Elzinga BM (2011) Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 16:1088–1095

Article  CAS  PubMed  Google Scholar 

Park H, Poo MM (2013) Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14:7–23